
AI Spotlight on YMAB
Company Description
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States.It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma.The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.
In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors.The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products.Y-mAbs Therapeutics, Inc.
was incorporated in 2015 and is headquartered in New York, New York.
Market Data
Last Price | 5.56 |
Change Percentage | 2.58% |
Open | 5.41 |
Previous Close | 5.42 |
Market Cap ( Millions) | 249 |
Volume | 587160 |
Year High | 20.9 |
Year Low | 5.28 |
M A 50 | 6.85 |
M A 200 | 11.21 |
Financial Ratios
FCF Yield | -8.79% |
Dividend Yield | 0.00% |
ROE | -24.61% |
Debt / Equity | 1.16% |
Net Debt / EBIDTA | 240.57% |
Price To Book | 2.68 |
Price Earnings Ratio | -10.4 |
Price To FCF | -11.38 |
Price To sales | 2.95 |
EV / EBITDA | -6.53 |
News
- Feb -25 - Y-mAbs Therapeutics, Inc. (YMAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
- Feb -20 - Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025
- Feb -06 - Y-mAbs to Present at the Oppenheimer 35ᵗʰ Annual Life Sciences Conference
- Feb -04 - YmAbs Therapeutics (YMAB) Loses -25.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
- Feb -03 - YmAbs Therapeutics (YMAB) Loses -26.93% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
- Jan -31 - Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting
- Jan -24 - Y-mAbs Therapeutics: Finding Direction Through The Murk Of Clinical Trials
- Jan -10 - Correcting & Replacing – Y-mAbs Provides Strategic Business Update and 2025 Priorities
- Jan -10 - Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit
- Jan -10 - Y-mAbs Provides Strategic Business Update and 2025 Priorities
- Dec -23 - Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- Dec -07 - Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting
- Nov -27 - Y-mAbs to Participate at Citi's 2024 Global Healthcare Conference
- Nov -08 - Y-mAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Lags Revenue Estimates
- Nov -08 - Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments
- Nov -04 - Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan
- Nov -01 - Will Y-mAbs Therapeutics, Inc. (YMAB) Report Negative Earnings Next Week? What You Should Know
- Oct -25 - Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast
- Oct -01 - Y-mAbs to Participate in Upcoming Investor Conferences in October
- Sep -06 - Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer Research
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Novel Antibody-based Therapeutic Products
Expected Growth : 10.27 %
What the company do ?
Y-mAbs Therapeutics' novel antibody-based therapeutic products target cancer and rare diseases, utilizing bispecific antibodies and antibody-drug conjugates for innovative treatments.
Why we expect these perspectives ?
Y-mAbs Therapeutics, Inc.'s novel antibody-based therapeutic products are driven by increasing demand for targeted cancer treatments, advancements in immunotherapy, and a growing pipeline of products in late-stage clinical trials. Strong partnerships, strategic collaborations, and a robust intellectual property portfolio also contribute to the company's 10.27% growth.
Y-Mabs Therapeutics, Inc. Products
Product Range | What is it ? |
---|---|
Naxitamab | A monoclonal antibody that targets GD2, a glycoprotein expressed on the surface of neuroblastoma cells, used for the treatment of high-risk neuroblastoma in patients one year of age and older and in bone marrow who have achieved at least a partial response to prior therapy. |
Omburtamab | A monoclonal antibody that targets B7-H3, a protein expressed on the surface of certain cancer cells, used for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma. |
YM155 | A small molecule inhibitor of survivin, a protein that inhibits apoptosis (cell death), used for the treatment of various types of cancer, including melanoma, lung, and breast cancer. |
Y-mAbs Therapeutics, Inc.'s Porter Forces
Threat Of Substitutes
Y-mAbs Therapeutics, Inc. has a moderate threat of substitutes due to the presence of alternative treatments and therapies for cancer and rare diseases. However, the company's focus on developing novel antibody-based therapies may reduce the threat of substitutes.
Bargaining Power Of Customers
Y-mAbs Therapeutics, Inc. has a low bargaining power of customers due to the lack of negotiating power of individual patients and the high demand for effective cancer and rare disease treatments.
Bargaining Power Of Suppliers
Y-mAbs Therapeutics, Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers of raw materials and services. However, the company's dependence on a few key suppliers may increase the bargaining power of suppliers.
Threat Of New Entrants
Y-mAbs Therapeutics, Inc. has a high threat of new entrants due to the growing interest in antibody-based therapies and the increasing investment in biotechnology research and development.
Intensity Of Rivalry
Y-mAbs Therapeutics, Inc. operates in a highly competitive industry with many established players and new entrants. The company faces intense rivalry from other biotechnology companies, which may lead to increased competition for market share and talent.
Capital Structure
Value | |
---|---|
Debt Weight | 1.39% |
Debt Cost | 3.95% |
Equity Weight | 98.61% |
Equity Cost | 7.79% |
WACC | 7.74% |
Leverage | 1.41% |
Y-mAbs Therapeutics, Inc. : Quality Control
Y-mAbs Therapeutics, Inc. passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
Company | Rational |
---|---|
LGND | Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which … |
ARDX | Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, … |
BYSI | BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent … |
APLT | Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for … |
CDXC | ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇

BeyondSpring
A-Score
1-Year Total Return ->
🥈

Ligand Pharmaceuticals
A-Score
1-Year Total Return ->
🥉

ChromaDex
A-Score
1-Year Total Return ->
4

Applied Therapeutics
A-Score
1-Year Total Return ->
5

Y-mAbs Therapeutics
A-Score
1-Year Total Return ->
6
